Evidence map›Paper›PMID 40970962›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Sophie C Siegmund, Adrien Holzgreve, Magdalena Schöll, Vera U Wenter, Gabriel T Sheikh, Maximilian Scheifele, Franz Josef Gildehaus, Simon Lindner, Matthias K Auer, Christian Lottspeich and 7 more

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sophie C SiegmundDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. sophie.siegmund@med.uni-muenchen.de.ORCID 0009-0003-3175-952X
Adrien HolzgreveDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Magdalena SchöllDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Vera U WenterDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Gabriel T SheikhDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Maximilian ScheifeleDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Franz Josef GildehausDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Simon LindnerDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Matthias K AuerDepartment of Internal Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Christian LottspeichDepartment of Internal Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Matthias KroißDepartment of Internal Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Svenja NöltingDepartment of Internal Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Friederike VölterDepartment of Internal Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Christine SpitzwegDepartment of Internal Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Christoph J AuernhammerDepartment of Internal Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Rudolf A WernerDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Mathias J ZacherlDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn somatostatin receptor (SSTR)-expressing tumors, theranostics with SSTR-directed imaging and therapy showed promising results regarding disease control. This study evaluated the use of PET imaging with [

methodsFive patients with metastatic paraganglioma (n = 3) or pheochromocytoma (n = 2) were included. Eligibility for PRRT was assessed by [

resultsAt baseline, all patients showed high lesional uptake, with the highest in the bone (mean SUV

conclusionIn metastatic PPGL, [

Indexed as

Adrenal Gland NeoplasmsParaganglioma, Extra-AdrenalPheochromocytomaPositron-Emission TomographyAdultAgedFemaleHumansMaleMiddle AgedNeoplasm MetastasisReceptors, SomatostatinReceptors, Somatostatin(3–6): [18F]SiTATEParagangliomaPeptide receptor radionuclide therapy (PRRT)PheochromocytomaSomatostatin receptor (SSTR)

Identifiers

PMID40970962
PMCPMC12860750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.